Skip to main content
. 2020 Dec 5;23(6):1010–1018. doi: 10.1093/ntr/ntaa258

Table 3.

Smoking cessation support overall and by trust

All participants
(n = 152)
Patient aware they were coming to a smoke-free environment n (%)
 Yes 89 (58.6)
 No 58 (38.2)
 Don’t know 4 (2.6)
 Missing 1 (0.7)
Asked about smoking status at the time of admission n (%)
 Yes 83 (54.6)
 No 42 (27.6)
 Don’t remember 27 (17.8)
Asked about smoking status at any other point n (%)
 Yes 12 (28.6)
 No 27 (64.3)
 Don’t remember 3 (7.1)
Offered support to stop smoking n (%)
 Yes 85 (55.9)
 No 65 (42.8)
 Missing 2 (1.3)
Type of support offered n (%)
 NRT 65 (76.5)
 Champix 0 (0)
 Zyban (Bupropion) 0 (0)
 Specialist treatment from someone that works on the ward 8 (9.4)
  Specialist treatment from someone that works outside the ward for a stop smoking service 1 (1.2)
  E-cigarettesa 8 (9.4)
 Other 13 (15.3)
 None 8 (9.4)
 Missing 1 (1.2)
Accepted support to stop smoking n (% of those who were offered support)
 Yes 41 (48.2)
 No 43 (50.6)
 Missing 1 (1.2)
Type of support accepted n (%)
 NRT 35 (85.4)
 Champix 0 (0)
 Zyban (Bupropion) 0 (0)
 Specialist treatment from someone that works on the ward 2 (4.9)
 Specialist treatment from someone that works outside the ward for a stop smoking service 0 (0)
 E-cigarettesa 4 (9.8)
 Other 8 (19.5)
 Missing 0 (0)
Type of NRT offered (multiple answers possible) n (%)
 Nicotine gum 13 (20.0)
 Nicotine patches 18 (27.7)
 Lozenges 4 (6.2)
 Inhaler 16 (24.6)
 Nasal spray 1 (1.5)
 Oral spray 4 (6.2)
 Microtab 4 (6.2)
 None of the above/missing 31 (47.7)
Type of NRT accepted (multiple answers possible) n (%)
 Nicotine gum 8 (22.9)
 Nicotine patches 14 (40.0)
 Lozenges 3 (8.6)
 Inhaler 13 (37.1)
 Nasal spray 0 (0)
 Oral spray 2 (5.7)
 Microtab 3 (8.6)
 None of the above/missing 2 (5.7)

aTrust A only (see details on policies in Methods section).

bNRT = Nicotine Replacement Therapy.